GSK aims to redefine the future of respiratory medicine at the European Respiratory Society International Congress
Issued: London, UK
For media and investors only
Download
(PDF, 168.7KB)
First presentation of SWIFT-1 and SWIFT-2 phase III trial data for ultra-long-acting biologic depemokimab in severe asthma
GSK aspires to change the course of disease,...
Zur Pressemeldung auf www.gsk.com